tirzepatide cardiovascular outcomes trial In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT Impact of Body Mass Index,
Pay in 4 interest-free payments of $5.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21























